Mabwell(SH:688062) Mei Ri Jing Ji Xin Wen·2025-12-19 06:09Group 1 - The central economic work conference emphasized that the long-term supportive conditions and basic trends of China's economy remain unchanged, urging confidence and the need to leverage advantages while addressing challenges to maintain economic stability and growth [2] - The pharmaceutical industry is highlighted as a key area for innovation, with a significant increase in the approval of innovative drugs, reaching 48 new class 1 innovative drugs in 2024, which is over five times the number approved in 2018 [2] - The biopharmaceutical sector is recognized as a long-term supported industry with characteristics such as long R&D cycles and high investment, and it has been designated as a key development area during the 14th Five-Year Plan [2] Group 2 - Liu Dato, Chairman and CEO of Maiwei Biotech, noted that the focus on new productive forces in the 14th Five-Year Plan and the recent conference's emphasis on innovation-driven growth have elevated the strategic importance of innovation, boosting industry confidence [3] - Source innovation is identified as the core competitiveness of biopharmaceutical companies, with Maiwei Biotech having developed several globally competitive innovative products [3] - The company aims to establish sustainable innovation capabilities by enhancing its technology platform and integrating AI technology into its R&D processes, which is expected to expand into more fields with technological advancements [3] Group 3 - The domestic biopharmaceutical industry has made significant progress over the past decade due to continuous innovation, although there is still room for improvement in basic research compared to developed countries [4] - Maiwei Biotech plans to continue focusing on source innovation and enhancing its capabilities in target innovation and technology innovation, aiming to promote the transformation of innovative results and improve global competitiveness [4]